MolMed Pulls Zalmoxis Cell Therapy In EU
Company Withdraws Marketing Authorization After Failed Trial Results
Executive Summary
The Italian biotech will redirect investment, initially reserved for Zalmoxis, to other activities that would better meet its business objectives.
You may also be interested in...
Japan’s AGC Makes Agreed €240m Bid For MolMed
AGC of Japan is offering to buy cell and gene therapy specialist MolMed SPA in a deal worth up to €240m and backed by the biotech’s biggest shareholder, Silvio Berlusconi’s Fininvest.
Kiadis Crushed By EMA Rejection Of T-Cell Therapy
The Dutch company's dataset on its stem cell transplant adjunct ATIR101 is not enough to satisfy European regulators as the standard of care in post-transplant patients has changed since the original filing.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.